Holen Sie sich die Stockscreener-App
16.11
1.77%
0.28
Handel nachbörslich:
16.14
0.03
+0.19%
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - MedCity News
Syndax Scores First-Mover Advantage With Approval Of Menin Inhibitor For Leukemia - Citeline
Syndax secures FDA OK for new kind of leukemia drug - BioPharma Dive
First Week of July 2025 Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
HC Wainwright Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
FDA approves Syndax’s Revuforj to treat leukaemia - Yahoo Finance
Syndax gets FDA okay for first-in-class leukaemia drug - pharmaphorum
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by StockNews.com - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.com - MarketBeat
US FDA approves Syndax's blood cancer drug - Reuters.com
Syndax's Revuforj Wins FDA Approval as First Menin Inhibitor for Acute Leukemia | SNDX Stock News - StockTitan
Simplify Asset Management Inc. Buys 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals By Investing.com - Investing.com South Africa
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint - Pharmaceutical Technology
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals - Investing.com UK
Syndax’s revumenib meets primary results in AML trial - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Inc Still Hasn’t Convinced Analysts? - Stocks Register
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL
Syndax falls after mid-stage data for leukemia drug - MSN
Syndax's Revumenib Trial Hits Key Endpoint with 47% Response Rate in AML Treatment | SNDX Stock News - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright - Defense World
Creative Planning Has $318,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
HC Wainwright Analysts Increase Earnings Estimates for SNDX - Defense World
Wellington Management Group LLP's Strategic Reduction in Syndax Pharmaceuticals Inc - GuruFocus.com
HC Wainwright Has Bullish Outlook for SNDX FY2024 Earnings - MarketBeat
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
The Goldman Sachs Group Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Syndax Pharmaceuticals outlines Q3 2024 progress By Investing.com - Investing.com Canada
Syndax and Royalty Pharma finalize $350 million deal | Pharmaceutical | The Pharmaletter - The Pharma Letter
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highligh - GuruFocus.com
Syndax Pharmaceuticals: Key Pipeline Developments and Financial Update - TipRanks
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax: Q3 Earnings Snapshot - San Francisco Chronicle
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Syndax Pharma Secures FDA Approval for Niktimvo Despite $84.1M Q3 Loss | SNDX Stock News - StockTitan
SNDXSyndax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Investors reevaluate this year’s obesity darling - STAT
Syndax Pharma to Present Revumenib & Niktimvo Updates at ASH 2024 Investor Event | SNDX Stock News - StockTitan
Syndax's Niktimvo Achieves 75% Response Rate in Pivotal GVHD Trial, New Data Shows | SNDX Stock News - StockTitan
Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com Canada
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - StockTitan
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):